Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

Related Articles by Review for PubMed (Select 23490599)

1.

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.

Hari Kumar KV, Shaikh A, Prusty P.

Diabetes Res Clin Pract. 2013 May;100(2):e55-8. doi: 10.1016/j.diabres.2013.01.020. Epub 2013 Mar 13.

PMID:
23490599
2.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
3.
4.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

5.

[New drugs; exenatide and sitagliptin].

van Bronswijk H, Dubois EA, Pijl H, Cohen AF.

Ned Tijdschr Geneeskd. 2008 Apr 12;152(15):876-9. Review. Dutch.

PMID:
18512528
6.

Incretin-based therapies in type 2 diabetes: a review of clinical results.

Bosi E, Lucotti P, Setola E, Monti L, Piatti PM.

Diabetes Res Clin Pract. 2008 Dec 15;82 Suppl 2:S102-7. doi: 10.1016/j.diabres.2008.10.003. Epub 2008 Nov 20. Review.

PMID:
19022515
7.

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.

Ryan GJ, Moniri NH, Smiley DD.

Am J Health Syst Pharm. 2013 Jul 1;70(13):1123-31. doi: 10.2146/ajhp120168. Review.

PMID:
23784159
8.

Incretin physiology and its role in type 2 diabetes mellitus.

Svec F.

J Am Osteopath Assoc. 2010 Jul;110(7 Suppl 7):eS20-4. Review.

PMID:
20644202
9.
10.

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.

Fakhoury WK, Lereun C, Wright D.

Pharmacology. 2010;86(1):44-57. doi: 10.1159/000314690. Epub 2010 Jul 12. Review.

11.

[New concepts in the treatment of type 2 diabetes].

Meier JJ, Schmidt WE, Klein HH.

Internist (Berl). 2007 Jul;48(7):698, 700-7. Review. German.

PMID:
17541529
12.

Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

Siddiqui NI.

Mymensingh Med J. 2009 Jan;18(1):113-24. Review.

PMID:
19182763
13.

Incretin-based therapies: review of current clinical trial data.

Peters A.

Am J Med. 2010 Mar;123(3 Suppl):S28-37. doi: 10.1016/j.amjmed.2009.12.007. Review.

PMID:
20206729
14.

[Exenatide--an alternative to insulin in the treatment of type 2 diabetes?].

Kjeldsen R, Sandbaek A.

Ugeskr Laeger. 2008 Sep 22;170(39):3039-43. Review. Danish.

PMID:
18822227
15.

Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.

Doggrell SA.

Expert Opin Pharmacother. 2011 Sep;12(13):2055-67. doi: 10.1517/14656566.2011.576671. Epub 2011 May 3. Review.

PMID:
21534885
16.
17.

The design of the liraglutide clinical trial programme.

Nauck MA.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:4-12. doi: 10.1111/j.1463-1326.2012.01573.x. Review.

PMID:
22405264
18.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
19.

[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].

Kleefstra N, van Hateren KJ, Houweling ST, Verhoeven S, Kooy A, Goudswaard AN, Bilo HJ.

Ned Tijdschr Geneeskd. 2010;154:A886. Review. Dutch.

PMID:
20298625
20.

Type 1 diabetes and cardiovascular disease.

Schnell O, Cappuccio F, Genovese S, Standl E, Valensi P, Ceriello A.

Cardiovasc Diabetol. 2013 Oct 28;12:156. doi: 10.1186/1475-2840-12-156. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk